Patents by Inventor Allan E. Titus

Allan E. Titus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210275470
    Abstract: A packaged, sealed container system for stable storage of a formulation of an oxygen-sensitive pharmaceutical compound, the packaged, sealed container system comprising a primary container including therein a formulation of an oxygen-sensitive pharmaceutical compound, a secondary outer container comprising a first flexible sheet layer, an opposing second flexible sheet layer, and a seal disposed along a common peripheral edge of the first and second flexible sheet layers, such that the primary container is disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. An oxygen scavenger is also disposed between and enclosed by the first and second flexible sheet layers of the secondary outer container. The oxygen scavenger is in fluid communication with the contents of the primary container.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
    Inventors: Steven M. Cope, Allan E. Titus
  • Patent number: 5650421
    Abstract: A pharmaceutical composition comprising a solution having an effective amount of famotidine, the solution having a pH in the range of about 4.5 to about 8.0, and a shelf life greater than 30 days.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: July 22, 1997
    Assignee: Baxter International Inc.
    Inventors: Allan E. Titus, Douglas G. Johnson
  • Patent number: 5304571
    Abstract: A pharmaceutical composition is provided comprising an unbuffered iso-osmotic aqueous formulation containing an effective amount of ranitidine for the treatment of conditions mediated through histamine H.sub.2 receptors. The formulation has a pH of greater than or equal to 5.0 and less than 6.5 and preferably includes an osmotic adjusting agent chosen from the group consisting of dextrose and sodium chloride.
    Type: Grant
    Filed: July 8, 1992
    Date of Patent: April 19, 1994
    Assignee: Baxter International Inc.
    Inventors: Douglas G. Johnson, Allan E. Titus
  • Patent number: 5169864
    Abstract: A pharmaceutical composition is provided comprising an unbuffered iso-osmotic aqueous formulation containing an effective amount of ranitidine for the treatment of conditions mediated through histamine H.sub.2 receptors. The formulation has a pH of greater than or equal to 5.0 and less than 6.5 and preferably includes an osmotic adjusting agent chosen from the group consisting of dextrose and sodium chloride.
    Type: Grant
    Filed: November 15, 1991
    Date of Patent: December 8, 1992
    Assignee: Baxter International Inc.
    Inventors: Douglas G. Johnson, Allan E. Titus